Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients. Huuhtanen J, Kasanen HH, Peltola K, Lonnberg T, et al. J Clin Invest 2023 Jan 31:e164809. doi: 10.1172/JCI164809.

Read + Share

Amedeo Smart

Independent Medical Education

Huuhtanen J, Kasanen HH, Peltola K, Lonnberg T, et al. Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients. J Clin Invest 2023 Jan 31:e164809. doi: 10.1172/JCI164809.
PMID: 36719749